Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source
Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
0.1 1990
0.1002887 1991
0.10055649 1992
0.10106859 1993
0.10186635 1994
0.10262048 1995
0.10366092 1996
0.1053155 1997
0.10679635 1998
0.1082599 1999
0.10914559 2000
0.10949104 2001
0.10958589 2002
0.10927723 2003
0.10858819 2004
0.10766949 2005
0.10709219 2006
0.10654507 2007
0.10602207 2008
0.10551913 2009
0.10500377 2010
0.10449093 2011
0.1042609 2012
0.10374183 2013
0.1035028 2014
0.10325197 2015
0.10486099 2016
0.10459884 2017
0.10432987 2018
0.10435234 2019
0.1040623 2020
0.10478504 2021
2022
Middle East & North Africa | Prevalence of HIV, total (% of population ages 15-49)
Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source